Familial Mediterranean fever (FMF) is the prototype of a group of hereditary inflammatory disorders. Patients experience short, self resolving, attacks of fever and serosal inflammation (peritonitis, arthritis, pleuritis).
Familial Mediterranean fever (FMF) is the prototype of a group of hereditary inflammatory disorders. Patients experience short, self resolving, attacks of fever and serosal inflammation (peritonitis, arthritis, pleuritis). 1 Although between attacks patients totally recover clinically, biological markers of inflammation (Serum Amyloid A protein, C Reactive Protein) sometimes remain elevated. 2, 3 The gene for this recessive disorder (MEFV) was identified 4 years ago by a positional cloning strategy. 4, 5 Screening for MEFV mutations has provided the first specific tool for diagnosing FMF, which can now be differentiated from the various other inflammatory conditions. However, it has been proposed that some MEFV variants may predispose to inflammation in general, [6] [7] [8] and indeed, preferential association with other inflammatory conditions has been reported. [9] [10] [11] The function of MEFV is still unknown. The disease phenotype and the almost exclusive expression of MEFV in leukocytes suggest that the corresponding protein plays an important role in the inflammatory cascade. [12] [13] [14] Some inflammatory mediators such as cytokines have been shown to be involved in the pathogenesis of FMF. [15] [16] [17] [18] The cytokine network has been studied in many circumstances in clinically diagnosed patients, ie during and between attacks, both on and off colchicine treatment, and after ex vivo induction, as well as in controls. The secreted levels of pro-inflammatory cytokines are enhanced during attacks, whereas during attack-free periods they do not differ or are slightly higher than in healthy subjects.
The present study is the first investigation of cytokines (i) at the transcriptional level, and (ii) in genetically ascertained patients. We have compared messenger RNA (mRNA) levels of four pro-inflammatory cytokines, tumor necrosis factor alpha (TNF-␣), interleukin 1 beta (IL-1␤), interleukin 6 (IL-6) and interleukin 8 (IL-8) in FMF patients in clinical remission and in healthy controls. TNF-␣ plays a key role in the inflammatory process by stimulating production of IL-1, which has a pyretic action; IL-6, promotes the release of acute phase reactants, and IL-8, is a chemoattractant.
The FMF group comprised 44 patients, whose composition is shown in Table 1 . 19 They were all in attack-free intervals upon blood sampling, based on clinical criteria: (i) no fever, no pain, no sign of inflammation, (ii) the time of their last attack was systematically documented, and happened at least 3 weeks earlier. The control group comprised 31 mutation-free healthy volunteers, unrelated to the patient group. We set up a multiplex RT-PCR strategy to quantify the cytokine mRNA levels relative to the hypoxanthine phosporibosyltransferase (HPRT) housekeeping gene, which was an internal control. 20 A typical experiment is shown in Figure 1 . We noted large individual variations of all cytokine expression in healthy controls and genetically ascertained FMF patients (Figure 2a) . The mean ratios of TNF-␣, IL-1␤, IL-6 and IL-8 cytokine/HPRT were all significantly higher in FMF patients than in controls, P = 0.01, P = 0.008, P = 0.02, P = 0.001 respectively. This could reflect a pre-activated state of the cells in attack-free FMF patients, which could progress into an acute phase response following an This group contains two patients homozygous for M680I (G/A) mutation.
Figure 1
Cytokine gene mRNA expression measured by RT-PCR analysis. Peripheral blood leukocytes (PBLs) were purified from heparinized blood and mRNA were prepared by TRIZOL extraction according to the manufacturer's protocol (GibcoBRL, France). One g total RNA was reversed transcribed with 200 U of M-MLV reverse transcriptase (GibcoBRL, France). The cDNA was amplified with AmpliTaq Gold (PE Biosystems, Foster City, CA, USA) for 30 cycles (annealing temperature 60°C), using standard conditions. Oligonucleotide PCR primers were as follows: HPRT (213 bp), 5Ј-TGTAATGACCAGTCAACAGGG-3Ј and 5Ј-TGGCTTATATCCAA-CACTTCG-3Ј; IL-1␤ (249 bp), 5Ј-GGCAGACTCAAATTCCAGCT-3Ј and 5Ј-GGACAGGATATGGAGCAACA-3Ј; IL-8 (289 bp), 5Ј-ATGACTTCCAAGCTGGCCGTG-3Ј and 5Ј-TCTCAGCCCTCTTC AAAAACTTCTC-3Ј; TNF-␣ (355 bp), 5Ј-CGGGACGTGGAGCT GGCCGAGGAG-3Ј and 5Ј-CACCAGCTGGTTATCTCTCAGC TC-3Ј; IL-6 (628 bp), 5Ј-ATGAACTCCTTCTCCACAAGCGC-3Ј and 5Ј-AAGAGCCCTCAGGCTGGACTG-3Ј. The amplified products were separated by electrophoresis on an 8% acrylamide gel and visualized after ethidium bromide staining. HC, healthy controls; FMF, genetically ascertained FMF patients; MW, molecular weight (BioMarker, Eurogentec).
inflammatory initiating or propagating process. A subclinical inflammation has already been proposed for FMF patients during remission.
2,3
In vitro stimulation of monocytes from healthy controls with a number of proinflammatory mediators resulted in increased levels of MEFV mRNA. 12, 14 It is quite possible that the molecular mechanisms underlying FMF are due to an imbalance in cytokine/MEFV expression levels. We thus investigated the impact of the most common FMFassociated genotype, M694V/M694V, which is known to be correlated with a severe disease course. [21] [22] [23] We observed no significant difference in cytokine mRNA levels between M694V/M694V patients and other FMF patients with a different genotype (Figure 2b) .
Finally, we assessed the effect of colchicine treatment (Figure 2c ). Kiraz et al 18 has reported a substantial decrease of the serum cytokines after colchicine treatment. By contrast, we observed no difference between treated and untreated patients, suggesting that the therapeutic effect of colchicine occurs by inhibiting the translation, processing or secretion of the cytokines leading to a reduction in the soluble serum levels.
Altogether, our results suggest that the cytokine transcriptional pathway is misregulated in attack-free FMF patients. Cytokine mRNA levels do not seem to be influenced either by MEFV genotype or colchicine treatment.
